Please login to the form below

Not currently logged in
Email:
Password:

PvP Biologics

This page shows the latest PvP Biologics news and features for those working in and with pharma, biotech and healthcare.

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

Deal includes upfront payment plus up to $330m in milestones. Takeda’s ‘build to buy’ strategy of partnering has resulted in a takeover deal for coeliac disease drug developer PvP Biologics. ... The approach taken with the PvP partnership mirrors

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    It proved to be a very busy month for Takeda with the company paying $35m to PvP Biologics for KumaMax for coeliac disease which is in preclinical development.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics